Cytokine Expression Profiles in Children and Adolescents with Tic Disorders.

Cytokine Expression Profiles in Children and Adolescents with Tic Disorders. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Cytokine Expression Profiles in Children and Adolescents with Tic Disorders. Ozgur Kutuk, Meryem Ozlem Kutuk, Ali Evren Tufan, Fethiye Kilicaslan, and 16 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3813261/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 9 You are reading this latest preprint version Abstract The etiology of tic disorders (TDs) is not precisely known, although several lines of evidence suggest involvement of the immune system in pathogenesis. Here, we aimed to determine the expression levels of pro-inflammatory and anti-inflammatory cytokines in children with TD and compare them with those of healthy controls. Furthermore, we also evaluated their association with clinical variables in the TD group. Within the study period, 88 children with tic disorders and 111 healthy control children were enrolled. Most children with tic disorders were diagnosed with Tourette’s disorder (n = 47, 53.4%) or persistent motor tic disorder (n = 39, 44.3%), while the remainder (n = 2, 2.3%) were diagnosed with persistent vocal tic disorder. We found that children with tic disorders had significantly elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression, while healthy control cases presented with increased levels of IL-17. Our findings provide a molecular landscape of cytokine expression in children with TD, which may suggest a proinflammatory state not affected by the presence of comorbidity and symptom severity. Delineating the contribution of alterations in the immune system to the pathogenesis of tic disorders will have critical implications for diagnosis and therapeutic interventions. Health sciences/Diseases Health sciences/Diseases/Psychiatric disorders Health sciences/Health care/Quality of life Health sciences/Risk factors Tic disorders Cytokines Immune system Inflammation Tourette syndrome Introduction Tics are defined as “sudden, rapid, recurrent, nonrhythmic motor movements and/or vocalizations, generally preceded by premonitory somatosensory urges.” The DSM-5 defines five tic disorders: provisional tic disorder, persistent motor or vocal tic disorder, Tourette’s disorder (also known as Tourette syndrome), other specified tic disorder, and unspecified tic disorder 1 . Epidemiological studies suggest that most tics among children involve males (male to female ratio is 4:1) and are transient, while persistent/chronic cases involve symptoms lasting more than 12 months. Children may display either simple (affecting one muscle group/body part) or complex (affecting several muscle groups/body parts or purposeful movements) motor/vocal tics. The prevalence of Tic disorders among children may be 3.0–4.0%, while that of Tourette’s Disorder may vary between 0.3-1.0% 1–3 . Tics start mostly in preschool or early school years with motor tics preceding vocal tics, and symptoms wax and wane to peak around puberty and recede in adolescence. Only 5.0–10.0% of cases continue into adulthood. Importantly, isolated cases of tic disorders (TD) among children are rare. Obsessions/compulsions (22.0–66.0%), attention deficit/hyperactivity disorder (ADHD, 55.0–60.0%), autism spectrum disorder (ASD, up to 22.8%), impulse/anger control problems (25.0–75.0%), and academic/neuropsychological problems frequently accompany TD 1 , 3 . The etiology of tic disorders is complex and multifactorial, probably including multiple genetic and non-genetic factors, such as environmental exposures and immune-mediated mechanisms. Consequently, this complexity was suggested to contribute to the heterogeneous disease phenotypes 1 – 4 . Studies conducted in the last three decades suggest that immune mechanisms may play a role in the development of TD. For instance, various studies suggest that children with TD may have elevated levels of proinflammatory cytokines such as TNF-α, IL-1β, IL-2, IL-6, IL-8, IL-12, IL-17, and IFN-γ 5 . TD among children was found to be associated with autoimmune disorders such as asthma, allergic rhinitis, allergic conjunctivitis and possibly eczema and food allergies 6 . Furthermore, TD and related syndromes have been shown to display abnormalities in microglial functioning 7 . Consistent with a role of immune signaling in TD-related disorders, injection of soluble IL-2 and IL-6 receptors was found to induce motor stereotypies in rats, which correlated with their deposition in the striatum, thalamus, and various cortical regions 8 , 9 . Exposure to maternal acute/chronic inflammation in utero was found to be associated with various neurodevelopmental disorders, including TD, in the offspring 10 . Cytokine levels among children with TD may be related to both comorbidities and symptom severity 11 , 12 . Moreover, dopamine itself was shown to mediate the pathogenesis of TD and exert immunomodulatory effects 13 . In agreement with this observation, atypical antipsychotics, which are used to manage tics, were found to display peripheral effects on the immune system 14 . Despite the accumulating evidence of immune mechanisms in TD among children and adolescents, to the best of our knowledge, no study has evaluated cytokine expression levels among Turkish children with TD. Previously, one study from Turkey reported changes in cytokine levels among children with OCD 15 . Herein, we examined the expression levels of IL-1β, IL-1α, IL-4, IL-6, IL-17, TNF-α, and TGF-β in peripheral blood mononuclear cells (PBMCs) in children with tics and healthy controls and determine the correlations between cytokine levels and clinical features to determine their contributions in children and adolescents with tic disorders. Materials and methods Study centers, sampling, and ethics This study was conducted at the Child and Adolescent Psychiatry Departments from seven centers and involved patients followed up with TD diagnosis in these centers (persistent (chronic) motor or vocal tic disorder [307.22, ICD-10 F95.1] and Tourette’s disorder [307.23, ICD-10 F95.2] as per DSM-5) 1 . The diagnoses of potentially eligible patients were corroborated with clinical interviews. The inclusion criteria for the TD group were a diagnosis of persistent motor/vocal tic disorder or Tourette’s disorder without known genetic syndromes and/or chronic neurological/medical conditions. Patients with intellectual disabilities (according to developmental history, mental status examination and academic achievement), autism spectrum disorders, PANDAS/PANSS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci/Pediatric Acute Onset Neuropsychiatric Syndrome) and psychosis were excluded. Informed consent was obtained from the parents of the children included in the study, and the children provided verbal/written assent. The study was carried out in accordance with the Declaration of Helsinki and local laws and regulations. The study protocol was approved by the Institutional Review Board (IRB) of Inonu University (No:2014/ 237). The control participants were recruited from children coming for routine control visits in the departments of pediatrics in the study centers. They were matched in terms of gender and age to children with TD. Inclusion criteria for control children were lack of lifetime psychopathology in psychiatric interviews. The exclusion criteria for both children with TD and controls were acute respiratory or infectious disease, history of cardiovascular, endocrine, neurological, or other disorders/factors known to affect inflammatory indices, and history of receiving steroids and intravenous gamma globulin within the last 6 months prior to the study visit. Psychometric evaluations Children’s Depression Inventory (CDI) is a 27-item self-report scale was developed to evaluate subjective symptoms of depression among 6- to 17-year-old children. The Turkish version was previously found to be valid and reliable. CDI was completed by children ≥ 8 years old in this study. Children scoring above 19 were accepted to display clinically significant depressive symptoms as per the reliability and validity study 16 , 17 . State-Trait Anxiety Inventory for Children (STAI-C) is a 40-item self-report scale was developed to evaluate symptoms of state and trait anxiety 18 , 19 . The STAI-C was completed by children ≥ 8 years old in this study. Children scoring above the median on the STAI-C-Trait were considered to have significant trait anxiety. Maudsley Obsessive Compulsive Symptom Checklist (MOCSL) is a 30-item self-report scale evaluates subjectively reported obsessive symptoms 20 . MOCSL was completed by children ≥ 8 years old in this study. Yale Global Tic Severity Scale (YGTSS) is a semi-structured, clinician-applied interview assesses the severity of tics for the past week. Motor and vocal tics are scored separately between 0 and 5 according to frequency, number, severity, complexity, and disability. Higher scores indicate greater severity, and finally, a clinical impairment score is added to form a total score 21 . Sample collection, qRT‒PCR and ELISA assays 10 mL of blood were collected into PAXGene Vacutainer tubes (Qiagen, Hilden, Germany), and RNA was isolated using the PAXGene Blood RNA Kit as described by the manufacturer. RNA integrity and quality were confirmed using an Agilent 2100 Bioanalyzer (Agilent Inc., Santa Clara, CA, USA). mRNA expression profile of cytokines was determined by using using QuantiTect Primer assays as described before 22 . To evaluate the concordance between serum cytokine levels and mRNA expression data, serum samples from children with TD and healthy control children were isolated and stored at − 80°C. Serum concentrations of IL-4 (Catalog #: D4050), IL-1α (Catalog #: DLA50), IL-1β (Catalog #: DLB50), TGF-β (Catalog #: DB100B), IL-17 (Catalog #: D1700), IL-6 (Catalog #: D6050) and TNF-α (Catalog #: DTA00D) were measured by using Quantikine enzyme-linked immunosorbent assays according to the protocol of the manufacturer (R&D Systems, Minneapolis, MN, USA). Statistical analysis to evaluate the significance of serum cytokine levels in different groups was conducted by means of Student’s t -test module on GraphPad Prism 10.0.2 software (San Diego, CA, USA). In all statistical analyses, p < 0.05 was considered significant. Statistical analyses Data were entered into a database prepared with Statistical Program for Social Sciences (SPSS™, IBM Inc., Armonk, NY) Version 22.0. Analyses were conducted with SPSS and with Jamovi (The Jamovi Project, https://www.jamovi.org ) Version 2.3.21. Nominal data were summarized as counts and frequencies, while quantitative data were summarized as the means and standard deviations or medians and interquartile ranges (IQRs) depending on normality and outliers. Comparisons between groups were conducted with chi-square tests for nominal variables. Yates’, Fisher’s, and likelihood ratio corrections were used as needed. Bivariate correlations between symptom severities and cytokine expression levels were evaluated using Spearman correlation analyses. Multivariate analysis of variance (MANOVA) with follow-up ANOVA was used to evaluate the effects of diagnosis on cytokine expression levels. P was set at 0.05 (two-tailed). Bonferroni corrections were used to adjust for multiple comparisons (Gaetano J. Holm‒Bonferroni sequential correction: An Excel TM calculator. 2018. https://www.researchgate.net./profile/Justin_Gaetano2 ). Effect sizes for significant findings were also reported. Results Within the study period, 88 children with tic disorders (n = 64, 72.7% male) and 111 control children (n = 74, 66.7% male) were enrolled. The mean ages of children with tic disorders and control children were 11.2 (SD = 3.1) and 12.0 (SD = 3.2) years, respectively. The groups did not differ significantly in terms of gender (χ2 = 0.6, p = 0.444, Yates’ correction) or mean age (t [197] =-1.9, p = 0.063, Student’s t test for independent groups). Other sociodemographic and familial variables of children with tic disorders and control children are illustrated in Table 1 . Table 1 Sociodemographic and familial features of children with tic disorders and control children N (%) Tic Disorder (n = 88) Control (n = 111) χ 2/dF or t P* E.S.** Educational status Not attending school 1 (1.1) 3 (2.7) 12.7/4 0.013 0.25 Kindergarten/preschool 6 (6.8) 1 (0.9) Primary school 34 (38.6) 26 (23.4) Secondary school 28 (31.8) 51 (45.9) High school 19 (21.6) 30 (27.0) Maternal age (years) 37.9 (6.7) 38.7 (7.1) -0.8/197 0.419 - Maternal education Primary school or lower 47 (53.4) 47 (42.7) 4.0/3 0.266 - Secondary school 10 (11.4) 9 (8.2) High school 14 (15.9) 23 (20.9) University or higher 17 (19.3) 31 (28.2) Maternal vocation Housewife 70 (79.5) 75 (67.6) 7.8/4 0.167 - Worker 2 (2.3) 5 (4.5) Civil servant 12 (13.6) 25 (22.5) Artisan 3 (3.4) 4 (3.6) Retired 1 (1.1) 0 (0.0) Paternal age (years) 42.0 (6.5) 41.3 (10.2) 0.6/197 0.581 - Paternal education Primary school or lower 29 (33.0) 32 (28.8) 0.8/3 0.841 - Secondary school 9 (10.2) 9 (8.1) High school 23 (26.1) 32 (28.8) University or higher 27 (30.7) 38 (34.2) Paternal vocation Jobless 3 (3.4) 1 (0.9) 7.0/4 0.222 - Worker 23 (26.1) 23 (20.7) Civil servant 27 (30.7) 36 (32.4) Artisan 30 (34.1) 40 (36.0) Retired 5 (5.7) 7 (6.3) Family status Intact/Nuclear 85 (96.6) 97 (87.4) 5.3/1 0.023 0.16 Separated/widowed/divorced 3 (3.4) 14 (12.6) Maternal psychopathology present 14 (15.9) 11 (9.9) 1.1/1 0.292 - Paternal psychopathology present 7 (8.0) 6 (5.4) 0.2/1 0.664 - *Chi square test with likelihood ratio, Yates’ corrections, Fisher’s exact test and t test for independent groups, **Phi and Cramer’s V. Control healthy children were significantly more likely to attend secondary and high schools than children with tic disorders, while they were less likely to live in intact, nuclear families. Apart from those, no significant differences emerged between groups. Most children with tic disorders were diagnosed with Tourette’s disorder (n = 47, 53.4%) or persistent motor tic disorder (n = 39, 44.3%), while the remainder (n = 2, 2.3%) were diagnosed with persistent vocal tic disorder. According to evaluations with the Yale Global Tic Disorder Severity Scale, mean scores for motor and vocal tics were 13.7 (SD = 4.9) and 5.2 (SD = 6.2), respectively. The mean global impairment and total scores were 29.2 (SD = 11.4) and 48.1 (SD = 18.6), respectively. Most children were classified as having either moderate (n = 40, 45.5%) or significant (n = 32, 36.4%) tics, while children with mild (n = 9, 10.2%) and severe (n = 7, 8.0%) tics were rarer. Additionally, most of the children had either one (n = 47, 53.4%) or two (n = 9, 10.2%) comorbid diagnoses (Median = 1.0, IQR = 1.0). The most common comorbid diagnoses were attention deficit/hyperactivity disorder (ADHD, n = 38, 43.2%), anxiety disorder (n = 13, 14.8%) and obsessive-compulsive disorder (OCD, n = 8, 9.1%). Of note, one child each (1.1%) was diagnosed with trichotillomania, childhood onset speech fluency disorder, enuresis, and oppositional defiant disorder. Most children were receiving pharmacological treatment (n = 72, 81.8%) with either one (n = 41, 46.6%) or two (n = 31, 35.2%) agents. The most common psychopharmacological treatments were aripiprazole (n = 42, 48.9%), methylphenidate (n = 15, 17.0%) and atomoxetine/risperidone/haloperidol (n = 12, 13.6%, each). Eight of the children (9.1%) were treated with SSRIs, while only one (1.1%) received olanzapine treatment. Self-reported symptoms of anxiety, depression, and obsessive-compulsive disorder among children with tic disorders and control children are listed in Table 2 . Table 2 Self-reported anxiety, depression, and obsessive-compulsive disorder symptoms among children with tic disorder and control children Median (IQR) Tic Disorder (n = 88) Control (n = 111) Z P* E.S. State-Trait Anxiety Inventory for Children- State 33.0 (10.3) 31.0 (10.0) -1.8 0.072 0.13 State-Trait Anxiety Inventory for Children- Trait 36.0 (12.0) 35.0 (10.0) -1.3 0.189 - Children’s Depression Inventory 10.0 (10.0) 8.0 (8.0) -1.6 0.108 - Maudsley Obsessive Compulsive Symptom Checklist 16.0 (9.0) 14.5 (10.0) -2.1 0.036 14.9 *Mann‒Whitney U test, E.S.: Effect Size In bivariate comparisons, children with tic disorder tended to have elevated levels of state anxiety and obsessive-compulsive symptom scores. Children with Tourette Disorder, Persistent Motor and Vocal tic disorders did not differ significantly in terms of self-reported symptoms (Mann‒Whitney U test, p > 0.05). Bivariate correlations of psychometric measures between the YGTSS- Total Tic Score and Global Impairment score revealed that only global impairment correlated significantly with the MoCA score (Spearman’s rank order correlation rho = 0.003, rho’= 0.021, Holm‒Bonferroni corrected). Less than half of the TD children had trait (n = 36, 40.9%) or state (n = 35, 39.8%) anxiety above the median, while only ten (11.4%) reported clinically significant depressive symptoms. Finally, we compared children with tic disorders and control children in terms of the expression of cytokines (i.e., IL-1α, IL-1β, TNF-α, IL-6, TGF-β, IL-17, and IL-4) by means of qRT‒PCR. Apart from TNF-α (p = 0.159) and IL-6 (p = 0.198) among children with tics and IL-17 among controls (p = 0.129, Kolmogorov‒Smirnov test with Lilliefors correction), none of the cytokines conformed to assumptions of normality. Covariance matrices of dependent variables were not equal across groups (Box’s M = 218.0, F = 7.5, p = 0.000), and only the error variances for IL-17 were equal (p = 0.393, Levene’s test). Therefore, interleukin levels across groups were compared with multivariate analysis of variance (MANOVA) with Pillai’s trace method. According to MANOVA, the groups differed significantly in terms of interleukin levels (F [7.0, 191.0] = 13.2, p = 0.000, partial η2 = 0.33). The results of univariate ANOVAs and interleukin levels across groups are illustrated in Table 3 . In addition, we evaluated the serum levels of cytokines in children with tic disorders and healthy control children by using ELISA to evaluate the concordance of qPCR results with serum protein levels. As shown in Fig. S1 , serum IL-1β, TNF-α, IL-6, and IL-4 levels were higher in children with tic disorders than in healthy controls, in line with the qRT‒PCR data. Furthermore, we could not detect any significant change in IL-1α and TGF-β levels in concordance with the qRT‒PCR results. These results may indicate that the increased expression of cytokines in children with tic disorders is a consequence of reprogrammed gene expression in PBMCs. Although we could not detect a significant alteration in IL-17 serum levels, we observed a trend for lower IL-17 serum levels in children with tic disorders (Fig. S1 ). Hence, this finding may suggest that cellular mechanisms other than transcriptional regulation could mediate the secretion and stability of IL-17. Table 3 Interleukin levels in children with tic disorders and control children Mean (SD) Tic Disorder (n = 88) Control (n = 111) F P* Partial η2 IL-1α 1.7 (0.8) 1.8 (0.7) 0.3 0.562 0.00 IL-1β 2.1 (1.2) 1.9 (0.8) 4.2 0.042 0.02 TNF-α 2.3 (1.1) 1.7 (0.7) 20.0 0.000 0.09 IL-6 3.1 (1.9) 1.7 (0.6) 55.2 0.000 0.22 TGF-β 1.7 (1.0) 1.7 (0.6) 0.00 0.961 0.00 IL-17 1.8 (0.9) 2.2 (0.8) 10.4 0.001 0.05 IL-4 2.0 (1.1) 1.6 (0.7) 10.1 0.002 0.05 *ANOVA with Bonferroni correction, IL: interleukin, TNF: tumor necrosis factor, TGF: tumor growth factor. According to univariate ANOVAs, children with tic disorders had significantly elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression, while controls had significantly elevated levels of IL-17 expression. The type of TD did not affect cytokine expression levels (Mann‒Whitney U test, p > 0.05). Among children with tic disorders, state anxiety scores correlated significantly and positively with IL-17 levels (rho = 0.32, p = 0.006), while among control children, state anxiety correlated significantly and negatively with IL-6 levels (rho=- 0.25, p = 0.026). Moreover, self-reported obsessive compulsive symptom scores correlated significantly and negatively with IL-4 levels (rho= -0.22, p = 0.049) among controls. Apart from those, no significant correlations emerged between interleukin levels and self-reported anxiety, depression, and obsessive-compulsive disorder symptoms. YGTSS-total tic and impairment scores did not correlate significantly with cytokine levels. Discussion This multicenter, cross-sectional, case‒control study evaluated the expression levels of cytokines in peripheral blood mononuclear cells of children diagnosed with Tic disorders and compared them with controls. Complex neurobiological and genetic mechanisms, alteration of iron metabolism, and environmental factors are thought to interact with each other in the etiology of TD, and immune dysfunction may be a promising avenue of research in the onset and development of tic disorders 4 , 23 – 27 . In our study, children with tic disorders had significantly elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression, while controls had significantly elevated levels of IL-17 expression. There were no significant differences between the TD groups in terms of cytokine levels. Among children with tic disorders, state anxiety scores correlated significantly and positively with IL-17 expression levels. The gender ratios of children with TD in our sample, their mean age and features of comorbid diagnoses conform to those reported in previous studies 2 , 3 . Henceforth, children with TD in our study reported significantly elevated levels of obsessive-compulsive symptoms compared to controls. Reflecting the effectiveness of atypical antipsychotics in the management of TD, almost half of our sample group was prescribed aripiprazole while more than four-fifths were receiving psychopharmacological treatment either for TD or for comorbid conditions 28 . Cytokines are multifunctional pleiotropic proteins that play crucial roles in cell-to-cell communication and cellular activation. Besides, many cytokines can act as neuromodulators and their expression is strictly regulated at peripheral and central nervous systems by means of neurotransmitters 29 . A recent meta-analysis found elevated levels of increased levels of proinflammatory cytokines in pediatric patients with Tourette syndrome, including TNF-α and IL-6 5 . Consistent with this analysis, we found elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression among children with TD, while state anxiety among those children correlated positively with IL-17 levels. Among these cytokines, IL-1β, TNF-α, IL-6 and IL-17 are pro-inflammatory, while IL-4 is mainly anti-inflammatory. Underscoring this observation, IL-6 is produced by most cell lines in the CNS, is neurotrophic for midbrain dopaminergic neurons as well as cholinergic neurons in the basal forebrain and septum, increases dopaminergic and serotonergic activity in the hippocampus and prefrontal cortex, regulates neuronal excitability and sleep, and elevated levels were reported in various psychopathologies and neurodevelopmental disorders, including TD 30 . IL-6 levels are also known to be reduced after treatment with antipsychotics 31 . In fact, Tao et al. reported increased IL-6 serum concentration in children with TD compared with control group, which includes 1724 patients and 550 healthy control subjects 32 . In contrast to our results and previous reports, they found lower IL-4, IL-10 and TNF-α levels in TD patients 33 , 34 . Similarly, Matz et al. also reported decreased TNF-α levels in children with Tourette’s syndrome with no alteration of IL-6 35 . However, Bos-Veneman et al. did not detect any significant difference between IL-4, IL-10 and TNF-α levels between patients and healthy controls 12 . The inconsistency in these studies may be due to different methodologies to determine serum cytokine levels, medications, presence of comorbidities, maternal autoimmunity, or age of patients 32 , 36 . TNF-α regulates the activation of microglia and astrocytes, regulation of blood‒brain barrier permeability, glutamatergic neurotransmission, and synaptic plasticity 37 . In fact, preclinical studies suggest that it may affect serotonergic and dopaminergic neurotransmission 38 . An increase in TNF-α levels would increase the permeability of the blood‒brain barrier and lead to an enhanced autoimmune response, along with greater dopamine release in the basal ganglia, which in turn contribute to the clinical symptoms of TS and related disorders 39 – 41 . It is worth noting that TNF-α and IL-6 were shown to be significantly increased in the peripheral blood of patients with Tourette’s syndrome in a recent meta-analysis 5 . IL-17 is a pro-inflammatory cytokine that acts synergistically with other pro-inflammatory cytokines and plays a role in neurotoxicity and autoimmunity 42 . Increased IL-17 levels have been previously reported in neurodegenerative, neurodevelopmental, and psychiatric disorders 43 , 44 . Therefore, higher IL-17 levels were reported to cause cell loss among dopaminergic neurons, while dopaminergic neurotransmission was found to modulate IL-17 secretion 45 , 46 . Surprisingly, we found reduced IL-17 expression in children with tic disorders compared with healthy control subjects. IL-4 is an anti-inflammatory cytokine that has paradoxical effects in the central nervous system. It may protect neurons against sepsis, ischemia and multiple sclerosis while contributing to the degeneration of dopaminergic neurons in the substantia nigra in the presence of inflammation 47 . Moreover, IL-4 levels may play a role in synaptic homeostasis, and exposure to elevated levels in utero may increase the risk of neurodevelopmental disorders in the fetus 48 . TGF-β is an immunosuppressive cytokine that also plays a role in neurodevelopment and synapse formation 49 . It was reported that lack of TGF-β led to disorganization in the extracellular matrix, neurodegeneration, microgliosis, reductions in synaptophysin, and defects in glutamatergic and GABAergic synapses 50 . On the other hand, overexpression of TGF-β was also found to disrupt the extracellular matrix and lead to seizures/motor incoordination and behavioral abnormalities 51 . Although TGF-β overexpression has been demonstrated to induce different behavioral consequences depending on the developmental stage, children with tic disorders in our study did not display changes in TGF-β expression levels compared to healthy controls. Accordingly, our results may support the presence of a pro-inflammatory status among Turkish children with TD, which was not affected by the presence of comorbidity and symptom severity. The lack of effects of comorbidity and symptom severity may be due to the limited sample size. Additionally, the limited number of children with mild or severe symptoms may have affected our power to evaluate the relationships of symptom severity with cytokine levels. Our results should be evaluated within their limitations. First, our results may be valid only for patients with Tourette’s Disorder and Persistent Motor Tic Disorder receiving treatment at the study centers and those without comorbid chronic neurological/medical conditions. Children with persistent vocal tic disorder were also limited in our sample, and future studies should enroll more patients with this diagnosis. Second, we excluded patients with comorbid intellectual disability/autism spectrum disorder, which may affect our results. Third, we evaluated intellectual disability in our sample according to psychiatric interviews, developmental history, academic achievement and mental status examination, and evaluation of intellectual functioning with valid psychometric measures (e.g., Wechsler Intelligence Scale for Children-Fourth Edition, WISC-IV) may have enriched our results. Fourth, most of our sample was receiving treatment, especially with antipsychotics, which may have affected cytokine levels. Fifth, evaluation of depression, anxiety, and obsessive-compulsive symptoms with clinician-rated measures in addition to personal reports may prove more valuable. Sixth, self-reports of depression, anxiety and obsessive-compulsive symptoms may be subject to reporting and recall bias in addition to shared method variance. Seventh, rather than unstructured clinical interviews, the use of semi-structured interviews (e.g., K-SADS-PL Turkish version) may be preferable in clinical evaluations. Last, in addition to cytokine levels, other measures of inflammation may be added to provide a more comprehensive battery. Regardless of those limitations, our results support the presence of a pro-inflammatory status among Turkish children with TD, which was not affected by the presence of comorbidity and symptom severity. Future studies may enroll children with diverse age ranges and symptom severities to evaluate inflammatory status among Turkish children with TD. In conclusion, our study adds to the ever-growing evidence base supporting the importance of the immune system in the pathophysiology of TS and related disorders. Recent research is progressively unveiling a complex interplay between neural transmission, immune response regulation and endocrine systems, which might provide further insight into the natural history of TS and its relationships with environmental stressors, especially infections 52 . The cross-sectional and correlational nature of our study design precludes hypotheses on causality. However, considering the role of dopamine in the modulation of immune cells via autocrine/paracrine routes as well as the expression of dopamine receptors on lymphocytes, prospective longitudinal studies may evaluate the role of the hypothesized hyperdopaminergic state of children with TD on their immune responses. The role of aberrant immunity in the brain development of children with neurodevelopmental disorders, including those with TD, also awaits further study. This avenue of research requires the development of more valid animal models as well as a larger availability of brain specimens. Once the complex interplay of neurodevelopment, immunity and environmental stressors is elucidated in more detail, the effects of immunotherapy with antibodies or antibody components targeting specific cytokines (e.g., IL-6) may be evaluated in preclinical models. These potential therapies may prevent peripheral cytokine receptors from crossing the blood‒brain barrier and prevent the induction of inflammatory cascades in the periphery with downstream effects. Additionally, the effects of anti-inflammatory agents such as cyclooxygenase inhibitors or n-acetylcysteine may be evaluated as potential treatments for TD. Understanding the role of immune abnormalities in the pathogenesis of tic disorders may not only aid in our understanding of the mechanism driving this disorder but may also provide biological markers that can be utilized clinically in diagnosis, the determination of symptom severity, and therapeutic interventions. We look forward to future progress in this field, which has the potential to elucidate new pathological mechanisms and therapeutic targets in TS based on neural-immune interactions. Declarations Acknowledgments None declared. Compliance with ethics guidelines Meryem Ozlem Kutuk, Ali Evren Tufan, Fethiye Kilicaslan, Cem Gokcen, Gulen Guler Aksu, Cigdem Yektas, Hasan Kandemir, Fatma Celik, Tuba Mutluer, Ahmet Buber, Mehmet Karadag, Nurdan Coban, Seyma Coskun, Zehra Hangul, Ebru Altintas, Ufuk Acikbas, Aslı Giray, Yeliz Aka, Bilkay Basturk and Ozgur Kutuk declare that they have no conflict of interest. All authors have given approval for this version to be published. The study was approved by the appropriate institutional and/or national research ethics committee and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study. Data availability The datasets used and/or analysed during the current study available from the corresponding author on reasonable request. References Posar, A. & Visconti, P. Autism Spectrum Disorder and the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5): The Experience of 10 Years. Turk Arch Pediatr 58, 658–659, doi: 10.5152/TurkArchPediatr.2023.23149 (2023). Szejko, N. et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment. Eur Child Adolesc Psychiatry 31, 383–402, doi: 10.1007/s00787-021-01842-2 (2022). Roessner, V., Hoekstra, P. J. & Rothenberger, A. Tourette's disorder and other tic disorders in DSM-5: a comment. Eur Child Adolesc Psychiatry 20, 71–74, doi: 10.1007/s00787-010-0143-3 (2011). Robertson, M. M. et al. Gilles de la Tourette syndrome. Nat Rev Dis Primers 3, 16097, doi: 10.1038/nrdp.2016.97 (2017). Li, Y. et al. Profiles of Proinflammatory Cytokines and T Cells in Patients With Tourette Syndrome: A Meta-Analysis. Front Immunol 13, 843247, doi: 10.3389/fimmu.2022.843247 (2022). Huang, J., Li, R., Li, L., Song, Y. & Jin, L. The relationship between allergic diseases and tic disorders: A systematic review and meta-analysis. Neurosci Biobehav Rev 132, 362–377, doi: 10.1016/j.neubiorev.2021.12.004 (2022). Frick, L. & Pittenger, C. Microglial Dysregulation in OCD, Tourette Syndrome, and PANDAS. J Immunol Res 2016, 8606057, doi: 10.1155/2016/8606057 (2016). Patel, A. et al. Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS One 7, e41623, doi: 10.1371/journal.pone.0041623 (2012). Zalcman, S. S., Patel, A., Mohla, R., Zhu, Y. & Siegel, A. Soluble cytokine receptors (sIL-2Ralpha, sIL-2Rbeta) induce subunit-specific behavioral responses and accumulate in the cerebral cortex and basal forebrain. PLoS One 7, e36316, doi: 10.1371/journal.pone.0036316 (2012). Han, V. X. et al. Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Transl Psychiatry 11, 71, doi: 10.1038/s41398-021-01198-w (2021). Gabbay, V. et al. A cytokine study in children and adolescents with Tourette's disorder. Prog Neuropsychopharmacol Biol Psychiatry 33, 967–971, doi: 10.1016/j.pnpbp.2009.05.001 (2009). Bos-Veneman, N. G. et al. Cytokines and soluble adhesion molecules in children and adolescents with a tic disorder. Prog Neuropsychopharmacol Biol Psychiatry 34, 1390–1395, doi: 10.1016/j.pnpbp.2010.06.028 (2010). Arreola, R. et al. Immunomodulatory Effects Mediated by Dopamine. J Immunol Res 2016, 3160486, doi: 10.1155/2016/3160486 (2016). Alvarez-Herrera, S. et al. Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Front Endocrinol (Lausanne) 11, 195, doi: 10.3389/fendo.2020.00195 (2020). Simsek, S., Yuksel, T., Cim, A. & Kaya, S. Serum Cytokine Profiles of Children with Obsessive-Compulsive Disorder Shows the Evidence of Autoimmunity. Int J Neuropsychopharmacol 19, doi: 10.1093/ijnp/pyw027 (2016). Kovacs, M. Rating scales to assess depression in school-aged children. Acta Paedopsychiatr 46, 305–315 (1981). Rosen, M. G. & Grochowalski, J. H. Change Score and Subscore Precision and Reliability of the Children's Depression Inventory. Assessment, 10731911231204832, doi: 10.1177/10731911231204832 (2023). Mohlman, J. et al. Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group. Int J Geriatr Psychiatry 27, 549–556, doi: 10.1002/gps.2752 (2012). Knowles, K. A. & Olatunji, B. O. Specificity of trait anxiety in anxiety and depression: Meta-analysis of the State-Trait Anxiety Inventory. Clin Psychol Rev 82, 101928, doi: 10.1016/j.cpr.2020.101928 (2020). Mataix-Cols, D., Lawrence, N. S., Wooderson, S., Speckens, A. & Phillips, M. L. The Maudsley Obsessive-Compulsive Stimuli Set: validation of a standardized paradigm for symptom-specific provocation in obsessive-compulsive disorder. Psychiatry Res 168, 238–241, doi: 10.1016/j.psychres.2008.05.007 (2009). Leckman, J. F. et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28, 566–573, doi: 10.1097/00004583-198907000-00015 (1989). Kutuk, M. O. et al. Cytokine expression profiles in Autism spectrum disorder: A multi-center study from Turkey. Cytokine 133, 155152, doi: 10.1016/j.cyto.2020.155152 (2020). Gorman, D. A. & Abi-Jaoude, E. Uncovering the complexity of Tourette syndrome, little by little. Br J Psychiatry 204, 6–8, doi: 10.1192/bjp.bp.113.135996 (2014). Paschou, P., Fernandez, T. V., Sharp, F., Heiman, G. A. & Hoekstra, P. J. Genetic susceptibility and neurotransmitters in Tourette syndrome. Int Rev Neurobiol 112, 155–177, doi: 10.1016/B978-0-12-411546-0.00006-8 (2013). Kanaan, A. S. et al. Convergent imaging-transcriptomic evidence for disturbed iron homeostasis in Gilles de la Tourette syndrome. Neurobiol Dis 185, 106252, doi: 10.1016/j.nbd.2023.106252 (2023). Tsetsos, F. et al. Genome-wide Association Study Points to Novel Locus for Gilles de la Tourette Syndrome. Biol Psychiatry, doi: 10.1016/j.biopsych.2023.01.023 (2023). Lamothe, H., Tamouza, R., Hartmann, A. & Mallet, L. Immunity and Gilles de la Tourette syndrome: A systematic review and meta-analysis of evidence for immune implications in Tourette syndrome. Eur J Neurol 28, 3187–3200, doi: 10.1111/ene.14983 (2021). Farhat, L. C. et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. Lancet Child Adolesc Health 7, 112–126, doi: 10.1016/S2352-4642(22)00316-9 (2023). Steinman, L. Inflammatory cytokines at the summits of pathological signal cascades in brain diseases. Sci Signal 6, pe3, doi: 10.1126/scisignal.2003898 (2013). Kummer, K. K., Zeidler, M., Kalpachidou, T. & Kress, M. Role of IL-6 in the regulation of neuronal development, survival and function. Cytokine 144, 155582, doi: 10.1016/j.cyto.2021.155582 (2021). Marcinowicz, P. et al. A Meta-Analysis of the Influence of Antipsychotics on Cytokines Levels in First Episode Psychosis. J Clin Med 10, doi: 10.3390/jcm10112488 (2021). Tao, Y. et al. Changes of Cytokines in Children With Tic Disorder. Front Neurol 12, 800189, doi: 10.3389/fneur.2021.800189 (2021). Leckman, J. F. et al. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. Biol Psychiatry 57, 667–673, doi: 10.1016/j.biopsych.2004.12.004 (2005). Yeon, S. M. et al. A cytokine study of pediatric Tourette's disorder without obsessive compulsive disorder. Psychiatry Res 247, 90–96, doi: 10.1016/j.psychres.2016.11.005 (2017). Matz, J. et al. Altered monocyte activation markers in Tourette's syndrome: a case-control study. BMC Psychiatry 12, 29, doi: 10.1186/1471-244X-12-29 (2012). Jones, H. F. et al. Maternal autoimmunity and inflammation are associated with childhood tics and obsessive-compulsive disorder: Transcriptomic data show common enriched innate immune pathways. Brain Behav Immun 94, 308–317, doi: 10.1016/j.bbi.2020.12.035 (2021). McCoy, M. K. & Tansey, M. G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5, 45, doi: 10.1186/1742-2094-5-45 (2008). van Heesch, F. et al. Systemic tumor necrosis factor-alpha decreases brain stimulation reward and increases metabolites of serotonin and dopamine in the nucleus accumbens of mice. Behav Brain Res 253, 191–195, doi: 10.1016/j.bbr.2013.07.038 (2013). Rochfort, K. D. & Cummins, P. M. The blood-brain barrier endothelium: a target for pro-inflammatory cytokines. Biochem Soc Trans 43, 702–706, doi: 10.1042/BST20140319 (2015). Banks, W. A. & Erickson, M. A. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 37, 26–32, doi: 10.1016/j.nbd.2009.07.031 (2010). Martino, D., Dale, R. C., Gilbert, D. L., Giovannoni, G. & Leckman, J. F. Immunopathogenic mechanisms in tourette syndrome: A critical review. Mov Disord 24, 1267–1279, doi: 10.1002/mds.22504 (2009). Ghorbani, M. M. et al. Evaluation of IL-17 Serum Level, Brain Inflammation and Demyelination in Experimental Autoimmune Encephalomyelitis C57BL/6 Mice Model with Different Doses of Myelin Oligodendrocyte Glycoprotein. Iran J Allergy Asthma Immunol 18, 300–309, doi: 10.18502/ijaai.v18i3.1123 (2019). Green, H. F., Khosousi, S. & Svenningsson, P. Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson's Disease. J Parkinsons Dis 9, 705–709, doi: 10.3233/JPD-191699 (2019). Chen, J., Liu, X. & Zhong, Y. Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases. Front Aging Neurosci 12, 566922, doi: 10.3389/fnagi.2020.566922 (2020). Melnikov, M., Belousova, O., Murugin, V., Pashenkov capital Em, C. & Boysmall ka, C. o. C. A. The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J Neuroimmunol 292, 97–101, doi: 10.1016/j.jneuroim.2016.01.020 (2016). Nakano, K. et al. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 373, 286–291, doi: 10.1016/j.bbrc.2008.06.012 (2008). Bok, E., Cho, E. J., Chung, E. S., Shin, W. H. & Jin, B. K. Interleukin-4 Contributes to Degeneration of Dopamine Neurons in the Lipopolysaccharide-treated Substantia Nigra in vivo. Exp Neurobiol 27, 309–319, doi: 10.5607/en.2018.27.4.309 (2018). Hanuscheck, N. et al. Interleukin-4 receptor signaling modulates neuronal network activity. J Exp Med 219, doi: 10.1084/jem.20211887 (2022). Patel, M. R. & Weaver, A. M. Astrocyte-derived small extracellular vesicles promote synapse formation via fibulin-2-mediated TGF-beta signaling. Cell Rep 34, 108829, doi: 10.1016/j.celrep.2021.108829 (2021). Brionne, T. C., Tesseur, I., Masliah, E. & Wyss-Coray, T. Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40, 1133–1145, doi: 10.1016/s0896-6273(03)00766-9 (2003). Depino, A. M., Lucchina, L. & Pitossi, F. Early and adult hippocampal TGF-beta1 overexpression have opposite effects on behavior. Brain Behav Immun 25, 1582–1591, doi: 10.1016/j.bbi.2011.05.007 (2011). Elamin, I., Edwards, M. J. & Martino, D. Immune dysfunction in Tourette syndrome. Behav Neurol 27, 23–32, doi: 10.3233/BEN-120295 (2013). Additional Declarations No competing interests reported. Supplementary Files SupplementaryFigure1.pptx Supplementary Figure S1. Altered serum levels of cytokines in Turkish children with tic disorders (TD) and healthy controls. Serum samples from children with TD and healthy control children were evaluated by ELISA. The results are representative of 3 independent measurements and expressed as pg/mL or ng/mL, accordingly. ***, p<0.001, unpaired, two-tailed Student’s t test. Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 15 Jan, 2024 Reviews received at journal 02 Jan, 2024 Reviewers agreed at journal 31 Dec, 2023 Reviewers agreed at journal 30 Dec, 2023 Reviewers invited by journal 29 Dec, 2023 Editor assigned by journal 29 Dec, 2023 Editor invited by journal 29 Dec, 2023 Submission checks completed at journal 29 Dec, 2023 First submitted to journal 27 Dec, 2023 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3813261","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":264577087,"identity":"7e51b7c2-d0b9-4a93-927b-83309c7fb8b9","order_by":0,"name":"Ozgur Kutuk","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABE0lEQVRIiWNgGAWjYPCCBCBmY3zAwHAAyGBsYGAwgIni0cLDwMZsQLIWNgmIFhS7MQE///Fr0hUMaYn7JdLSKn/U3JE3Zz/cJl1QcJiBnz3HAJsWyYYzZZJnGHISeyTSjt3mOfbMcGdPYpv0DIPDDJI9b7BqMTjYkybZwFAB1JLedpuB7TDjhhuMbdI8BmkMBjew22JwmAehpfDHv8P2cC32uLQcYz8G1AJxGANv2+FEqBYbBgMJHH7p4WG2bDBIM+458yxZmrfvWfKGM4nN1kAtPBJnnhXgCLGHNxsqkmXb29MMP/74dsd2w/HjD2/z/JGQ429P3oA1lBl4DKARhy6OXTkIsD/ALTcKRsEoGAWjAAQA0W1gLrSeLN4AAAAASUVORK5CYII=","orcid":"","institution":"Sabancı University","correspondingAuthor":true,"prefix":"","firstName":"Ozgur","middleName":"","lastName":"Kutuk","suffix":""},{"id":264577088,"identity":"d0f8aaf2-a0e8-4802-84a7-677e400e4696","order_by":1,"name":"Meryem Ozlem Kutuk","email":"","orcid":"","institution":"Başkent University","correspondingAuthor":false,"prefix":"","firstName":"Meryem","middleName":"Ozlem","lastName":"Kutuk","suffix":""},{"id":264577089,"identity":"b82ccdfd-76d2-441f-b3ad-8e814e1ac9ee","order_by":2,"name":"Ali Evren Tufan","email":"","orcid":"","institution":"Bolu Abant Izzet Baysal University school of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Ali","middleName":"Evren","lastName":"Tufan","suffix":""},{"id":264577090,"identity":"3de07fef-90da-479b-85c7-e227d32932b7","order_by":3,"name":"Fethiye Kilicaslan","email":"","orcid":"","institution":"Harran University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Fethiye","middleName":"","lastName":"Kilicaslan","suffix":""},{"id":264577091,"identity":"a0f45165-6e72-475b-8eca-1f9a81557ae0","order_by":4,"name":"Cem Gokcen","email":"","orcid":"","institution":"Private Practice","correspondingAuthor":false,"prefix":"","firstName":"Cem","middleName":"","lastName":"Gokcen","suffix":""},{"id":264577092,"identity":"72b676c6-5dce-492c-981f-b8290c9f654a","order_by":5,"name":"Gulen Guler Aksu","email":"","orcid":"","institution":"Mersin University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Gulen","middleName":"Guler","lastName":"Aksu","suffix":""},{"id":264577093,"identity":"6333f530-b736-48d1-a8d7-f3741f16f6ab","order_by":6,"name":"Cigdem Yektas","email":"","orcid":"","institution":"Private Practice","correspondingAuthor":false,"prefix":"","firstName":"Cigdem","middleName":"","lastName":"Yektas","suffix":""},{"id":264577094,"identity":"d3c50bc4-1a60-47ea-910e-ef21c9c716ef","order_by":7,"name":"Hasan Kandemir","email":"","orcid":"","institution":"Pamukkale University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Hasan","middleName":"","lastName":"Kandemir","suffix":""},{"id":264577095,"identity":"8f452df4-4238-4d0c-ad98-901146e71aa3","order_by":8,"name":"Fatma Celik","email":"","orcid":"","institution":"Ankara Gazi Mustafa Kemal Occupational and Environmental Diseases Hospital","correspondingAuthor":false,"prefix":"","firstName":"Fatma","middleName":"","lastName":"Celik","suffix":""},{"id":264577096,"identity":"a9cea38c-36d5-4185-85a0-7ff5dfc1b981","order_by":9,"name":"Tuba Mutluer","email":"","orcid":"","institution":"Koc University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Tuba","middleName":"","lastName":"Mutluer","suffix":""},{"id":264577097,"identity":"f404d147-df48-4597-a6f6-e7e1507ec45e","order_by":10,"name":"Ahmet Buber","email":"","orcid":"","institution":"Pamukkale University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Ahmet","middleName":"","lastName":"Buber","suffix":""},{"id":264577098,"identity":"f11288b4-e2eb-483f-9cd2-3bfb88dc5964","order_by":11,"name":"Mehmet Karadag","email":"","orcid":"","institution":"Gaziantep University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Mehmet","middleName":"","lastName":"Karadag","suffix":""},{"id":264577099,"identity":"ed7bbb3f-532e-4e27-8bba-b0c2dbd2310d","order_by":12,"name":"Nurdan Coban","email":"","orcid":"","institution":"Adana City Training and Research Hospital","correspondingAuthor":false,"prefix":"","firstName":"Nurdan","middleName":"","lastName":"Coban","suffix":""},{"id":264577100,"identity":"ce50ad4f-7c79-4349-bc3c-0359d6511940","order_by":13,"name":"Seyma Coskun","email":"","orcid":"","institution":"Private Practice","correspondingAuthor":false,"prefix":"","firstName":"Seyma","middleName":"","lastName":"Coskun","suffix":""},{"id":264577101,"identity":"cef47c05-9979-4b94-9d01-e13e7c9d628b","order_by":14,"name":"Zehra Hangul","email":"","orcid":"","institution":"Gaziantep University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Zehra","middleName":"","lastName":"Hangul","suffix":""},{"id":264577102,"identity":"f4567111-3015-48d7-b683-c93ba55ec19d","order_by":15,"name":"Ebru Altintas","email":"","orcid":"","institution":"Başkent University","correspondingAuthor":false,"prefix":"","firstName":"Ebru","middleName":"","lastName":"Altintas","suffix":""},{"id":264577103,"identity":"184c04bf-e63c-4820-ab63-d565829b22cc","order_by":16,"name":"Ufuk Acikbas","email":"","orcid":"","institution":"Immunocore (United Kingdom)","correspondingAuthor":false,"prefix":"","firstName":"Ufuk","middleName":"","lastName":"Acikbas","suffix":""},{"id":264577104,"identity":"2a1ae0a1-5c46-4b84-a41e-9979cda31963","order_by":17,"name":"Asli Giray","email":"","orcid":"","institution":"Alanya Alaaddin Keykubat University","correspondingAuthor":false,"prefix":"","firstName":"Asli","middleName":"","lastName":"Giray","suffix":""},{"id":264577105,"identity":"04e6a330-f54a-4131-889a-1a6aa9ba4867","order_by":18,"name":"Yeliz Aka","email":"","orcid":"","institution":"Başkent University","correspondingAuthor":false,"prefix":"","firstName":"Yeliz","middleName":"","lastName":"Aka","suffix":""},{"id":264577106,"identity":"470b3530-303b-4e33-855b-37eda0501f5f","order_by":19,"name":"Bilkay Basturk","email":"","orcid":"","institution":"Başkent University","correspondingAuthor":false,"prefix":"","firstName":"Bilkay","middleName":"","lastName":"Basturk","suffix":""}],"badges":[],"createdAt":"2023-12-27 17:59:11","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3813261/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3813261/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":49031313,"identity":"eac9f2da-172e-48dd-8d6b-7f73e45b1489","added_by":"auto","created_at":"2024-01-01 19:06:35","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":346152,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3813261/v1/f5238617-7a40-47e1-b10e-926875925881.pdf"},{"id":49031274,"identity":"a8bba977-c762-453f-aeb2-d038ff0dd7b2","added_by":"auto","created_at":"2024-01-01 18:58:35","extension":"pptx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":385208,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary Figure S1. \u003c/strong\u003eAltered serum levels of cytokines in Turkish children with tic disorders (TD) and healthy controls.\u003cstrong\u003e \u003c/strong\u003eSerum samples from children with TD and healthy control children were evaluated by ELISA. The results are representative of 3 independent measurements and expressed as pg/mL or ng/mL, accordingly. ***, p\u0026lt;0.001, unpaired, two-tailed Student’s t test.\u003c/p\u003e","description":"","filename":"SupplementaryFigure1.pptx","url":"https://assets-eu.researchsquare.com/files/rs-3813261/v1/56700c851659a5bd859cbc2d.pptx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Cytokine Expression Profiles in Children and Adolescents with Tic Disorders.","fulltext":[{"header":"Introduction","content":"\u003cp\u003eTics are defined as \u0026ldquo;sudden, rapid, recurrent, nonrhythmic motor movements and/or vocalizations, generally preceded by premonitory somatosensory urges.\u0026rdquo; The DSM-5 defines five tic disorders: provisional tic disorder, persistent motor or vocal tic disorder, Tourette\u0026rsquo;s disorder (also known as Tourette syndrome), other specified tic disorder, and unspecified tic disorder \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. Epidemiological studies suggest that most tics among children involve males (male to female ratio is 4:1) and are transient, while persistent/chronic cases involve symptoms lasting more than 12 months. Children may display either simple (affecting one muscle group/body part) or complex (affecting several muscle groups/body parts or purposeful movements) motor/vocal tics. The prevalence of Tic disorders among children may be 3.0\u0026ndash;4.0%, while that of Tourette\u0026rsquo;s Disorder may vary between 0.3-1.0% \u003csup\u003e1\u0026ndash;3\u003c/sup\u003e. Tics start mostly in preschool or early school years with motor tics preceding vocal tics, and symptoms wax and wane to peak around puberty and recede in adolescence. Only 5.0\u0026ndash;10.0% of cases continue into adulthood. Importantly, isolated cases of tic disorders (TD) among children are rare. Obsessions/compulsions (22.0\u0026ndash;66.0%), attention deficit/hyperactivity disorder (ADHD, 55.0\u0026ndash;60.0%), autism spectrum disorder (ASD, up to 22.8%), impulse/anger control problems (25.0\u0026ndash;75.0%), and academic/neuropsychological problems frequently accompany TD \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. The etiology of tic disorders is complex and multifactorial, probably including multiple genetic and non-genetic factors, such as environmental exposures and immune-mediated mechanisms. Consequently, this complexity was suggested to contribute to the heterogeneous disease phenotypes\u003csup\u003e\u003cspan additionalcitationids=\"CR2 CR3\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eStudies conducted in the last three decades suggest that immune mechanisms may play a role in the development of TD. For instance, various studies suggest that children with TD may have elevated levels of proinflammatory cytokines such as TNF-α, IL-1β, IL-2, IL-6, IL-8, IL-12, IL-17, and IFN-γ \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. TD among children was found to be associated with autoimmune disorders such as asthma, allergic rhinitis, allergic conjunctivitis and possibly eczema and food allergies \u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Furthermore, TD and related syndromes have been shown to display abnormalities in microglial functioning \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Consistent with a role of immune signaling in TD-related disorders, injection of soluble IL-2 and IL-6 receptors was found to induce motor stereotypies in rats, which correlated with their deposition in the striatum, thalamus, and various cortical regions \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Exposure to maternal acute/chronic inflammation in utero was found to be associated with various neurodevelopmental disorders, including TD, in the offspring \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. Cytokine levels among children with TD may be related to both comorbidities and symptom severity \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Moreover, dopamine itself was shown to mediate the pathogenesis of TD and exert immunomodulatory effects \u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. In agreement with this observation, atypical antipsychotics, which are used to manage tics, were found to display peripheral effects on the immune system \u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. Despite the accumulating evidence of immune mechanisms in TD among children and adolescents, to the best of our knowledge, no study has evaluated cytokine expression levels among Turkish children with TD. Previously, one study from Turkey reported changes in cytokine levels among children with OCD \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eHerein, we examined the expression levels of IL-1β, IL-1α, IL-4, IL-6, IL-17, TNF-α, and TGF-β in peripheral blood mononuclear cells (PBMCs) in children with tics and healthy controls and determine the correlations between cytokine levels and clinical features to determine their contributions in children and adolescents with tic disorders.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy centers, sampling, and ethics\u003c/h2\u003e \u003cp\u003eThis study was conducted at the Child and Adolescent Psychiatry Departments from seven centers and involved patients followed up with TD diagnosis in these centers (persistent (chronic) motor or vocal tic disorder [307.22, ICD-10 F95.1] and Tourette\u0026rsquo;s disorder [307.23, ICD-10 F95.2] as per DSM-5) \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. The diagnoses of potentially eligible patients were corroborated with clinical interviews. The inclusion criteria for the TD group were a diagnosis of persistent motor/vocal tic disorder or Tourette\u0026rsquo;s disorder without known genetic syndromes and/or chronic neurological/medical conditions. Patients with intellectual disabilities (according to developmental history, mental status examination and academic achievement), autism spectrum disorders, PANDAS/PANSS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci/Pediatric Acute Onset Neuropsychiatric Syndrome) and psychosis were excluded. Informed consent was obtained from the parents of the children included in the study, and the children provided verbal/written assent. The study was carried out in accordance with the Declaration of Helsinki and local laws and regulations. The study protocol was approved by the Institutional Review Board (IRB) of Inonu University (No:2014/ 237). The control participants were recruited from children coming for routine control visits in the departments of pediatrics in the study centers. They were matched in terms of gender and age to children with TD. Inclusion criteria for control children were lack of lifetime psychopathology in psychiatric interviews. The exclusion criteria for both children with TD and controls were acute respiratory or infectious disease, history of cardiovascular, endocrine, neurological, or other disorders/factors known to affect inflammatory indices, and history of receiving steroids and intravenous gamma globulin within the last 6 months prior to the study visit.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003ePsychometric evaluations\u003c/h2\u003e \u003cp\u003eChildren\u0026rsquo;s Depression Inventory (CDI) is a 27-item self-report scale was developed to evaluate subjective symptoms of depression among 6- to 17-year-old children. The Turkish version was previously found to be valid and reliable. CDI was completed by children\u0026thinsp;\u0026ge;\u0026thinsp;8 years old in this study. Children scoring above 19 were accepted to display clinically significant depressive symptoms as per the reliability and validity study \u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. State-Trait Anxiety Inventory for Children (STAI-C) is a 40-item self-report scale was developed to evaluate symptoms of state and trait anxiety \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. The STAI-C was completed by children\u0026thinsp;\u0026ge;\u0026thinsp;8 years old in this study. Children scoring above the median on the STAI-C-Trait were considered to have significant trait anxiety. Maudsley Obsessive Compulsive Symptom Checklist (MOCSL) is a 30-item self-report scale evaluates subjectively reported obsessive symptoms \u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. MOCSL was completed by children\u0026thinsp;\u0026ge;\u0026thinsp;8 years old in this study. Yale Global Tic Severity Scale (YGTSS) is a semi-structured, clinician-applied interview assesses the severity of tics for the past week. Motor and vocal tics are scored separately between 0 and 5 according to frequency, number, severity, complexity, and disability. Higher scores indicate greater severity, and finally, a clinical impairment score is added to form a total score \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eSample collection, qRT‒PCR and ELISA assays\u003c/h2\u003e \u003cp\u003e10 mL of blood were collected into PAXGene Vacutainer tubes (Qiagen, Hilden, Germany), and RNA was isolated using the PAXGene Blood RNA Kit as described by the manufacturer. RNA integrity and quality were confirmed using an Agilent 2100 Bioanalyzer (Agilent Inc., Santa Clara, CA, USA). mRNA expression profile of cytokines was determined by using using QuantiTect Primer assays as described before \u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. To evaluate the concordance between serum cytokine levels and mRNA expression data, serum samples from children with TD and healthy control children were isolated and stored at \u0026minus;\u0026thinsp;80\u0026deg;C. Serum concentrations of IL-4 (Catalog #: D4050), IL-1α (Catalog #: DLA50), IL-1β (Catalog #: DLB50), TGF-β (Catalog #: DB100B), IL-17 (Catalog #: D1700), IL-6 (Catalog #: D6050) and TNF-α (Catalog #: DTA00D) were measured by using Quantikine enzyme-linked immunosorbent assays according to the protocol of the manufacturer (R\u0026amp;D Systems, Minneapolis, MN, USA). Statistical analysis to evaluate the significance of serum cytokine levels in different groups was conducted by means of Student\u0026rsquo;s \u003cem\u003et\u003c/em\u003e-test module on GraphPad Prism 10.0.2 software (San Diego, CA, USA). In all statistical analyses, p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered significant.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analyses\u003c/h2\u003e \u003cp\u003eData were entered into a database prepared with Statistical Program for Social Sciences (SPSS\u0026trade;, IBM Inc., Armonk, NY) Version 22.0. Analyses were conducted with SPSS and with Jamovi (The Jamovi Project, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.jamovi.org\u003c/span\u003e\u003cspan address=\"https://www.jamovi.org\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) Version 2.3.21. Nominal data were summarized as counts and frequencies, while quantitative data were summarized as the means and standard deviations or medians and interquartile ranges (IQRs) depending on normality and outliers. Comparisons between groups were conducted with chi-square tests for nominal variables. Yates\u0026rsquo;, Fisher\u0026rsquo;s, and likelihood ratio corrections were used as needed. Bivariate correlations between symptom severities and cytokine expression levels were evaluated using Spearman correlation analyses. Multivariate analysis of variance (MANOVA) with follow-up ANOVA was used to evaluate the effects of diagnosis on cytokine expression levels. P was set at 0.05 (two-tailed). Bonferroni corrections were used to adjust for multiple comparisons (Gaetano J. Holm‒Bonferroni sequential correction: An Excel \u003csup\u003eTM\u003c/sup\u003e calculator. 2018. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.researchgate.net./profile/Justin_Gaetano2\u003c/span\u003e\u003cspan address=\"https://www.researchgate.net./profile/Justin_Gaetano2\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). Effect sizes for significant findings were also reported.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eWithin the study period, 88 children with tic disorders (n\u0026thinsp;=\u0026thinsp;64, 72.7% male) and 111 control children (n\u0026thinsp;=\u0026thinsp;74, 66.7% male) were enrolled. The mean ages of children with tic disorders and control children were 11.2 (SD\u0026thinsp;=\u0026thinsp;3.1) and 12.0 (SD\u0026thinsp;=\u0026thinsp;3.2) years, respectively. The groups did not differ significantly in terms of gender (χ2\u0026thinsp;=\u0026thinsp;0.6, p\u0026thinsp;=\u0026thinsp;0.444, Yates\u0026rsquo; correction) or mean age (t [197] =-1.9, p\u0026thinsp;=\u0026thinsp;0.063, Student\u0026rsquo;s t test for independent groups). Other sociodemographic and familial variables of children with tic disorders and control children are illustrated in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSociodemographic and familial features of children with tic disorders and control children\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eN (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTic Disorder\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;88)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eControl\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;111)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eχ 2/dF or t\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eP*\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eE.S.**\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003eEducational status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNot attending school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e12.7/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e\u003cem\u003e0.013\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e\u003cem\u003e0.25\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKindergarten/preschool\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (0.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34 (38.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e26 (23.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSecondary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28 (31.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e51 (45.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHigh school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19 (21.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30 (27.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eMaternal age (years)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37.9 (6.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e38.7 (7.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e-0.8/197\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.419\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eMaternal education\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary school or lower\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47 (53.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e47 (42.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e4.0/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.266\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSecondary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10 (11.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9 (8.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHigh school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (15.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23 (20.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUniversity or higher\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17 (19.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e31 (28.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003eMaternal vocation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHousewife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70 (79.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e75 (67.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e7.8/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e0.167\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWorker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (2.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5 (4.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCivil servant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12 (13.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e25 (22.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eArtisan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (3.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4 (3.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRetired\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePaternal age (years)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42.0 (6.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e41.3 (10.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.6/197\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.581\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003ePaternal education\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary school or lower\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29 (33.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e32 (28.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.8/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.841\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSecondary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (10.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9 (8.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHigh school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23 (26.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e32 (28.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUniversity or higher\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27 (30.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e38 (34.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003ePaternal vocation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eJobless\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (3.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (0.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e7.0/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e0.222\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWorker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23 (26.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23 (20.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCivil servant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27 (30.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e36 (32.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eArtisan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30 (34.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e40 (36.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRetired\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (5.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7 (6.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eFamily status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIntact/Nuclear\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e85 (96.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e97 (87.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e5.3/1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cem\u003e0.023\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cem\u003e0.16\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSeparated/widowed/divorced\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (3.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14 (12.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eMaternal psychopathology present\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (15.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11 (9.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.1/1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.292\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePaternal psychopathology present\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (8.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (5.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.2/1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.664\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e*Chi square test with likelihood ratio, Yates\u0026rsquo; corrections, Fisher\u0026rsquo;s exact test and t test for independent groups, **Phi and Cramer\u0026rsquo;s V.\u003c/p\u003e \u003cp\u003eControl healthy children were significantly more likely to attend secondary and high schools than children with tic disorders, while they were less likely to live in intact, nuclear families. Apart from those, no significant differences emerged between groups. Most children with tic disorders were diagnosed with Tourette\u0026rsquo;s disorder (n\u0026thinsp;=\u0026thinsp;47, 53.4%) or persistent motor tic disorder (n\u0026thinsp;=\u0026thinsp;39, 44.3%), while the remainder (n\u0026thinsp;=\u0026thinsp;2, 2.3%) were diagnosed with persistent vocal tic disorder. According to evaluations with the Yale Global Tic Disorder Severity Scale, mean scores for motor and vocal tics were 13.7 (SD\u0026thinsp;=\u0026thinsp;4.9) and 5.2 (SD\u0026thinsp;=\u0026thinsp;6.2), respectively. The mean global impairment and total scores were 29.2 (SD\u0026thinsp;=\u0026thinsp;11.4) and 48.1 (SD\u0026thinsp;=\u0026thinsp;18.6), respectively. Most children were classified as having either moderate (n\u0026thinsp;=\u0026thinsp;40, 45.5%) or significant (n\u0026thinsp;=\u0026thinsp;32, 36.4%) tics, while children with mild (n\u0026thinsp;=\u0026thinsp;9, 10.2%) and severe (n\u0026thinsp;=\u0026thinsp;7, 8.0%) tics were rarer.\u003c/p\u003e \u003cp\u003eAdditionally, most of the children had either one (n\u0026thinsp;=\u0026thinsp;47, 53.4%) or two (n\u0026thinsp;=\u0026thinsp;9, 10.2%) comorbid diagnoses (Median\u0026thinsp;=\u0026thinsp;1.0, IQR\u0026thinsp;=\u0026thinsp;1.0). The most common comorbid diagnoses were attention deficit/hyperactivity disorder (ADHD, n\u0026thinsp;=\u0026thinsp;38, 43.2%), anxiety disorder (n\u0026thinsp;=\u0026thinsp;13, 14.8%) and obsessive-compulsive disorder (OCD, n\u0026thinsp;=\u0026thinsp;8, 9.1%). Of note, one child each (1.1%) was diagnosed with trichotillomania, childhood onset speech fluency disorder, enuresis, and oppositional defiant disorder. Most children were receiving pharmacological treatment (n\u0026thinsp;=\u0026thinsp;72, 81.8%) with either one (n\u0026thinsp;=\u0026thinsp;41, 46.6%) or two (n\u0026thinsp;=\u0026thinsp;31, 35.2%) agents. The most common psychopharmacological treatments were aripiprazole (n\u0026thinsp;=\u0026thinsp;42, 48.9%), methylphenidate (n\u0026thinsp;=\u0026thinsp;15, 17.0%) and atomoxetine/risperidone/haloperidol (n\u0026thinsp;=\u0026thinsp;12, 13.6%, each). Eight of the children (9.1%) were treated with SSRIs, while only one (1.1%) received olanzapine treatment. Self-reported symptoms of anxiety, depression, and obsessive-compulsive disorder among children with tic disorders and control children are listed in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSelf-reported anxiety, depression, and obsessive-compulsive disorder symptoms among children with tic disorder and control children\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian (IQR)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTic Disorder\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;88)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;111)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eZ\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eP*\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eE.S.\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eState-Trait Anxiety Inventory for Children- State\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e33.0 (10.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e31.0 (10.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-1.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.072\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.13\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eState-Trait Anxiety Inventory for Children- Trait\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e36.0 (12.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.0 (10.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-1.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.189\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eChildren\u0026rsquo;s Depression Inventory\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10.0 (10.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8.0 (8.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-1.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.108\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMaudsley Obsessive Compulsive Symptom Checklist\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16.0 (9.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14.5 (10.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003e0.036\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003e14.9\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"6\"\u003e*Mann‒Whitney U test, E.S.: Effect Size\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eIn bivariate comparisons, children with tic disorder tended to have elevated levels of state anxiety and obsessive-compulsive symptom scores. Children with Tourette Disorder, Persistent Motor and Vocal tic disorders did not differ significantly in terms of self-reported symptoms (Mann‒Whitney U test, p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Bivariate correlations of psychometric measures between the YGTSS- Total Tic Score and Global Impairment score revealed that only global impairment correlated significantly with the MoCA score (Spearman\u0026rsquo;s rank order correlation rho\u0026thinsp;=\u0026thinsp;0.003, rho\u0026rsquo;= 0.021, Holm‒Bonferroni corrected). Less than half of the TD children had trait (n\u0026thinsp;=\u0026thinsp;36, 40.9%) or state (n\u0026thinsp;=\u0026thinsp;35, 39.8%) anxiety above the median, while only ten (11.4%) reported clinically significant depressive symptoms.\u003c/p\u003e \u003cp\u003eFinally, we compared children with tic disorders and control children in terms of the expression of cytokines (i.e., IL-1α, IL-1β, TNF-α, IL-6, TGF-β, IL-17, and IL-4) by means of qRT‒PCR. Apart from TNF-α (p\u0026thinsp;=\u0026thinsp;0.159) and IL-6 (p\u0026thinsp;=\u0026thinsp;0.198) among children with tics and IL-17 among controls (p\u0026thinsp;=\u0026thinsp;0.129, Kolmogorov‒Smirnov test with Lilliefors correction), none of the cytokines conformed to assumptions of normality. Covariance matrices of dependent variables were not equal across groups (Box\u0026rsquo;s M\u0026thinsp;=\u0026thinsp;218.0, F\u0026thinsp;=\u0026thinsp;7.5, p\u0026thinsp;=\u0026thinsp;0.000), and only the error variances for IL-17 were equal (p\u0026thinsp;=\u0026thinsp;0.393, Levene\u0026rsquo;s test). Therefore, interleukin levels across groups were compared with multivariate analysis of variance (MANOVA) with Pillai\u0026rsquo;s trace method. According to MANOVA, the groups differed significantly in terms of interleukin levels (F [7.0, 191.0]\u0026thinsp;=\u0026thinsp;13.2, p\u0026thinsp;=\u0026thinsp;0.000, partial η2\u0026thinsp;=\u0026thinsp;0.33). The results of univariate ANOVAs and interleukin levels across groups are illustrated in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e. In addition, we evaluated the serum levels of cytokines in children with tic disorders and healthy control children by using ELISA to evaluate the concordance of qPCR results with serum protein levels. As shown in Fig. \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e, serum IL-1β, TNF-α, IL-6, and IL-4 levels were higher in children with tic disorders than in healthy controls, in line with the qRT‒PCR data. Furthermore, we could not detect any significant change in IL-1α and TGF-β levels in concordance with the qRT‒PCR results. These results may indicate that the increased expression of cytokines in children with tic disorders is a consequence of reprogrammed gene expression in PBMCs. Although we could not detect a significant alteration in IL-17 serum levels, we observed a trend for lower IL-17 serum levels in children with tic disorders (Fig. \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e). Hence, this finding may suggest that cellular mechanisms other than transcriptional regulation could mediate the secretion and stability of IL-17.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eInterleukin levels in children with tic disorders and control children\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTic Disorder\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;88)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;111)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eP*\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003ePartial η2\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIL-1α\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.7 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.8 (0.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.562\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIL-1β\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.1 (1.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.9 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003e0.042\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003e0.02\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTNF-α\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.3 (1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.7 (0.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e20.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003e0.000\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003e0.09\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIL-6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3.1 (1.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.7 (0.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003e0.000\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003e0.22\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTGF-β\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.7 (1.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.7 (0.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.961\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIL-17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.8 (0.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.2 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003e0.001\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003e0.05\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIL-4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.0 (1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.6 (0.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003e0.002\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003e0.05\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e*ANOVA with Bonferroni correction, IL: interleukin, TNF: tumor necrosis factor, TGF: tumor growth factor.\u003c/p\u003e \u003cp\u003eAccording to univariate ANOVAs, children with tic disorders had significantly elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression, while controls had significantly elevated levels of IL-17 expression. The type of TD did not affect cytokine expression levels (Mann‒Whitney U test, p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Among children with tic disorders, state anxiety scores correlated significantly and positively with IL-17 levels (rho\u0026thinsp;=\u0026thinsp;0.32, p\u0026thinsp;=\u0026thinsp;0.006), while among control children, state anxiety correlated significantly and negatively with IL-6 levels (rho=- 0.25, p\u0026thinsp;=\u0026thinsp;0.026). Moreover, self-reported obsessive compulsive symptom scores correlated significantly and negatively with IL-4 levels (rho= -0.22, p\u0026thinsp;=\u0026thinsp;0.049) among controls. Apart from those, no significant correlations emerged between interleukin levels and self-reported anxiety, depression, and obsessive-compulsive disorder symptoms. YGTSS-total tic and impairment scores did not correlate significantly with cytokine levels.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis multicenter, cross-sectional, case‒control study evaluated the expression levels of cytokines in peripheral blood mononuclear cells of children diagnosed with Tic disorders and compared them with controls. Complex neurobiological and genetic mechanisms, alteration of iron metabolism, and environmental factors are thought to interact with each other in the etiology of TD, and immune dysfunction may be a promising avenue of research in the onset and development of tic disorders \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan additionalcitationids=\"CR24 CR25 CR26\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. In our study, children with tic disorders had significantly elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression, while controls had significantly elevated levels of IL-17 expression. There were no significant differences between the TD groups in terms of cytokine levels. Among children with tic disorders, state anxiety scores correlated significantly and positively with IL-17 expression levels. The gender ratios of children with TD in our sample, their mean age and features of comorbid diagnoses conform to those reported in previous studies \u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Henceforth, children with TD in our study reported significantly elevated levels of obsessive-compulsive symptoms compared to controls. Reflecting the effectiveness of atypical antipsychotics in the management of TD, almost half of our sample group was prescribed aripiprazole while more than four-fifths were receiving psychopharmacological treatment either for TD or for comorbid conditions \u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. Cytokines are multifunctional pleiotropic proteins that play crucial roles in cell-to-cell communication and cellular activation. Besides, many cytokines can act as neuromodulators and their expression is strictly regulated at peripheral and central nervous systems by means of neurotransmitters \u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. A recent meta-analysis found elevated levels of increased levels of proinflammatory cytokines in pediatric patients with Tourette syndrome, including TNF-α and IL-6 \u003csup\u003e5\u003c/sup\u003e. Consistent with this analysis, we found elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression among children with TD, while state anxiety among those children correlated positively with IL-17 levels. Among these cytokines, IL-1β, TNF-α, IL-6 and IL-17 are pro-inflammatory, while IL-4 is mainly anti-inflammatory. Underscoring this observation, IL-6 is produced by most cell lines in the CNS, is neurotrophic for midbrain dopaminergic neurons as well as cholinergic neurons in the basal forebrain and septum, increases dopaminergic and serotonergic activity in the hippocampus and prefrontal cortex, regulates neuronal excitability and sleep, and elevated levels were reported in various psychopathologies and neurodevelopmental disorders, including TD \u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. IL-6 levels are also known to be reduced after treatment with antipsychotics \u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. In fact, Tao et al. reported increased IL-6 serum concentration in children with TD compared with control group, which includes 1724 patients and 550 healthy control subjects \u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. In contrast to our results and previous reports, they found lower IL-4, IL-10 and TNF-α levels in TD patients \u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e,\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e. Similarly, Matz et al. also reported decreased TNF-α levels in children with Tourette\u0026rsquo;s syndrome with no alteration of IL-6 \u003csup\u003e35\u003c/sup\u003e. However, Bos-Veneman et al. did not detect any significant difference between IL-4, IL-10 and TNF-α levels between patients and healthy controls \u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. The inconsistency in these studies may be due to different methodologies to determine serum cytokine levels, medications, presence of comorbidities, maternal autoimmunity, or age of patients \u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. TNF-α regulates the activation of microglia and astrocytes, regulation of blood‒brain barrier permeability, glutamatergic neurotransmission, and synaptic plasticity \u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. In fact, preclinical studies suggest that it may affect serotonergic and dopaminergic neurotransmission \u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. An increase in TNF-α levels would increase the permeability of the blood‒brain barrier and lead to an enhanced autoimmune response, along with greater dopamine release in the basal ganglia, which in turn contribute to the clinical symptoms of TS and related disorders \u003csup\u003e\u003cspan additionalcitationids=\"CR40\" citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e. It is worth noting that TNF-α and IL-6 were shown to be significantly increased in the peripheral blood of patients with Tourette\u0026rsquo;s syndrome in a recent meta-analysis \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. IL-17 is a pro-inflammatory cytokine that acts synergistically with other pro-inflammatory cytokines and plays a role in neurotoxicity and autoimmunity \u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e. Increased IL-17 levels have been previously reported in neurodegenerative, neurodevelopmental, and psychiatric disorders \u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e,\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e. Therefore, higher IL-17 levels were reported to cause cell loss among dopaminergic neurons, while dopaminergic neurotransmission was found to modulate IL-17 secretion \u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e,\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e. Surprisingly, we found reduced IL-17 expression in children with tic disorders compared with healthy control subjects. IL-4 is an anti-inflammatory cytokine that has paradoxical effects in the central nervous system. It may protect neurons against sepsis, ischemia and multiple sclerosis while contributing to the degeneration of dopaminergic neurons in the substantia nigra in the presence of inflammation \u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e. Moreover, IL-4 levels may play a role in synaptic homeostasis, and exposure to elevated levels in utero may increase the risk of neurodevelopmental disorders in the fetus \u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e. TGF-β is an immunosuppressive cytokine that also plays a role in neurodevelopment and synapse formation \u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. It was reported that lack of TGF-β led to disorganization in the extracellular matrix, neurodegeneration, microgliosis, reductions in synaptophysin, and defects in glutamatergic and GABAergic synapses \u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e. On the other hand, overexpression of TGF-β was also found to disrupt the extracellular matrix and lead to seizures/motor incoordination and behavioral abnormalities \u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. Although TGF-β overexpression has been demonstrated to induce different behavioral consequences depending on the developmental stage, children with tic disorders in our study did not display changes in TGF-β expression levels compared to healthy controls.\u003c/p\u003e \u003cp\u003eAccordingly, our results may support the presence of a pro-inflammatory status among Turkish children with TD, which was not affected by the presence of comorbidity and symptom severity. The lack of effects of comorbidity and symptom severity may be due to the limited sample size. Additionally, the limited number of children with mild or severe symptoms may have affected our power to evaluate the relationships of symptom severity with cytokine levels.\u003c/p\u003e \u003cp\u003eOur results should be evaluated within their limitations. First, our results may be valid only for patients with Tourette\u0026rsquo;s Disorder and Persistent Motor Tic Disorder receiving treatment at the study centers and those without comorbid chronic neurological/medical conditions. Children with persistent vocal tic disorder were also limited in our sample, and future studies should enroll more patients with this diagnosis. Second, we excluded patients with comorbid intellectual disability/autism spectrum disorder, which may affect our results. Third, we evaluated intellectual disability in our sample according to psychiatric interviews, developmental history, academic achievement and mental status examination, and evaluation of intellectual functioning with valid psychometric measures (e.g., Wechsler Intelligence Scale for Children-Fourth Edition, WISC-IV) may have enriched our results. Fourth, most of our sample was receiving treatment, especially with antipsychotics, which may have affected cytokine levels. Fifth, evaluation of depression, anxiety, and obsessive-compulsive symptoms with clinician-rated measures in addition to personal reports may prove more valuable. Sixth, self-reports of depression, anxiety and obsessive-compulsive symptoms may be subject to reporting and recall bias in addition to shared method variance. Seventh, rather than unstructured clinical interviews, the use of semi-structured interviews (e.g., K-SADS-PL Turkish version) may be preferable in clinical evaluations. Last, in addition to cytokine levels, other measures of inflammation may be added to provide a more comprehensive battery.\u003c/p\u003e \u003cp\u003eRegardless of those limitations, our results support the presence of a pro-inflammatory status among Turkish children with TD, which was not affected by the presence of comorbidity and symptom severity. Future studies may enroll children with diverse age ranges and symptom severities to evaluate inflammatory status among Turkish children with TD. In conclusion, our study adds to the ever-growing evidence base supporting the importance of the immune system in the pathophysiology of TS and related disorders. Recent research is progressively unveiling a complex interplay between neural transmission, immune response regulation and endocrine systems, which might provide further insight into the natural history of TS and its relationships with environmental stressors, especially infections \u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe cross-sectional and correlational nature of our study design precludes hypotheses on causality. However, considering the role of dopamine in the modulation of immune cells via autocrine/paracrine routes as well as the expression of dopamine receptors on lymphocytes, prospective longitudinal studies may evaluate the role of the hypothesized hyperdopaminergic state of children with TD on their immune responses. The role of aberrant immunity in the brain development of children with neurodevelopmental disorders, including those with TD, also awaits further study. This avenue of research requires the development of more valid animal models as well as a larger availability of brain specimens. Once the complex interplay of neurodevelopment, immunity and environmental stressors is elucidated in more detail, the effects of immunotherapy with antibodies or antibody components targeting specific cytokines (e.g., IL-6) may be evaluated in preclinical models. These potential therapies may prevent peripheral cytokine receptors from crossing the blood‒brain barrier and prevent the induction of inflammatory cascades in the periphery with downstream effects. Additionally, the effects of anti-inflammatory agents such as cyclooxygenase inhibitors or n-acetylcysteine may be evaluated as potential treatments for TD.\u003c/p\u003e \u003cp\u003eUnderstanding the role of immune abnormalities in the pathogenesis of tic disorders may not only aid in our understanding of the mechanism driving this disorder but may also provide biological markers that can be utilized clinically in diagnosis, the determination of symptom severity, and therapeutic interventions. We look forward to future progress in this field, which has the potential to elucidate new pathological mechanisms and therapeutic targets in TS based on neural-immune interactions.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone declared.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompliance with ethics guidelines\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMeryem Ozlem Kutuk, Ali Evren Tufan, Fethiye Kilicaslan, Cem Gokcen, Gulen Guler Aksu, Cigdem Yektas, Hasan Kandemir, Fatma Celik, Tuba Mutluer, Ahmet Buber, Mehmet Karadag, Nurdan Coban, Seyma Coskun, Zehra Hangul, Ebru Altintas, Ufuk Acikbas, Aslı Giray, Yeliz Aka, Bilkay Basturk\u003csup\u003e\u0026nbsp;\u003c/sup\u003eand Ozgur Kutuk declare that they have no conflict of interest. All authors have given approval for this version to be published. The study was approved by the appropriate institutional and/or national research ethics committee and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and/or analysed during the current study available from the corresponding author on reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003ePosar, A. \u0026amp; Visconti, P. Autism Spectrum Disorder and the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5): The Experience of 10 Years. Turk Arch Pediatr 58, 658\u0026ndash;659, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.5152/TurkArchPediatr.2023.23149\u003c/span\u003e\u003cspan address=\"10.5152/TurkArchPediatr.2023.23149\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSzejko, N. \u003cem\u003eet al.\u003c/em\u003e European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment. Eur Child Adolesc Psychiatry 31, 383\u0026ndash;402, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00787-021-01842-2\u003c/span\u003e\u003cspan address=\"10.1007/s00787-021-01842-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoessner, V., Hoekstra, P. J. \u0026amp; Rothenberger, A. Tourette's disorder and other tic disorders in DSM-5: a comment. Eur Child Adolesc Psychiatry 20, 71\u0026ndash;74, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00787-010-0143-3\u003c/span\u003e\u003cspan address=\"10.1007/s00787-010-0143-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRobertson, M. M. \u003cem\u003eet al.\u003c/em\u003e Gilles de la Tourette syndrome. Nat Rev Dis Primers 3, 16097, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrdp.2016.97\u003c/span\u003e\u003cspan address=\"10.1038/nrdp.2016.97\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, Y. \u003cem\u003eet al.\u003c/em\u003e Profiles of Proinflammatory Cytokines and T Cells in Patients With Tourette Syndrome: A Meta-Analysis. Front Immunol 13, 843247, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fimmu.2022.843247\u003c/span\u003e\u003cspan address=\"10.3389/fimmu.2022.843247\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang, J., Li, R., Li, L., Song, Y. \u0026amp; Jin, L. The relationship between allergic diseases and tic disorders: A systematic review and meta-analysis. Neurosci Biobehav Rev 132, 362\u0026ndash;377, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.neubiorev.2021.12.004\u003c/span\u003e\u003cspan address=\"10.1016/j.neubiorev.2021.12.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFrick, L. \u0026amp; Pittenger, C. Microglial Dysregulation in OCD, Tourette Syndrome, and PANDAS. \u003cem\u003eJ Immunol Res\u003c/em\u003e 2016, 8606057, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1155/2016/8606057\u003c/span\u003e\u003cspan address=\"10.1155/2016/8606057\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePatel, A. \u003cem\u003eet al.\u003c/em\u003e Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS One 7, e41623, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1371/journal.pone.0041623\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0041623\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZalcman, S. S., Patel, A., Mohla, R., Zhu, Y. \u0026amp; Siegel, A. Soluble cytokine receptors (sIL-2Ralpha, sIL-2Rbeta) induce subunit-specific behavioral responses and accumulate in the cerebral cortex and basal forebrain. PLoS One 7, e36316, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1371/journal.pone.0036316\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0036316\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHan, V. X. \u003cem\u003eet al.\u003c/em\u003e Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Transl Psychiatry 11, 71, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41398-021-01198-w\u003c/span\u003e\u003cspan address=\"10.1038/s41398-021-01198-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGabbay, V. \u003cem\u003eet al.\u003c/em\u003e A cytokine study in children and adolescents with Tourette's disorder. Prog Neuropsychopharmacol Biol Psychiatry 33, 967\u0026ndash;971, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.pnpbp.2009.05.001\u003c/span\u003e\u003cspan address=\"10.1016/j.pnpbp.2009.05.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBos-Veneman, N. G. \u003cem\u003eet al.\u003c/em\u003e Cytokines and soluble adhesion molecules in children and adolescents with a tic disorder. Prog Neuropsychopharmacol Biol Psychiatry 34, 1390\u0026ndash;1395, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.pnpbp.2010.06.028\u003c/span\u003e\u003cspan address=\"10.1016/j.pnpbp.2010.06.028\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArreola, R. \u003cem\u003eet al.\u003c/em\u003e Immunomodulatory Effects Mediated by Dopamine. \u003cem\u003eJ Immunol Res\u003c/em\u003e 2016, 3160486, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1155/2016/3160486\u003c/span\u003e\u003cspan address=\"10.1155/2016/3160486\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlvarez-Herrera, S. \u003cem\u003eet al.\u003c/em\u003e Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Front Endocrinol (Lausanne) 11, 195, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fendo.2020.00195\u003c/span\u003e\u003cspan address=\"10.3389/fendo.2020.00195\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimsek, S., Yuksel, T., Cim, A. \u0026amp; Kaya, S. Serum Cytokine Profiles of Children with Obsessive-Compulsive Disorder Shows the Evidence of Autoimmunity. Int J Neuropsychopharmacol 19, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/ijnp/pyw027\u003c/span\u003e\u003cspan address=\"10.1093/ijnp/pyw027\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKovacs, M. Rating scales to assess depression in school-aged children. Acta Paedopsychiatr 46, 305\u0026ndash;315 (1981).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRosen, M. G. \u0026amp; Grochowalski, J. H. Change Score and Subscore Precision and Reliability of the Children's Depression Inventory. Assessment, 10731911231204832, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/10731911231204832\u003c/span\u003e\u003cspan address=\"10.1177/10731911231204832\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMohlman, J. \u003cem\u003eet al.\u003c/em\u003e Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group. Int J Geriatr Psychiatry 27, 549\u0026ndash;556, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/gps.2752\u003c/span\u003e\u003cspan address=\"10.1002/gps.2752\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKnowles, K. A. \u0026amp; Olatunji, B. O. Specificity of trait anxiety in anxiety and depression: Meta-analysis of the State-Trait Anxiety Inventory. Clin Psychol Rev 82, 101928, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cpr.2020.101928\u003c/span\u003e\u003cspan address=\"10.1016/j.cpr.2020.101928\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMataix-Cols, D., Lawrence, N. S., Wooderson, S., Speckens, A. \u0026amp; Phillips, M. L. The Maudsley Obsessive-Compulsive Stimuli Set: validation of a standardized paradigm for symptom-specific provocation in obsessive-compulsive disorder. Psychiatry Res 168, 238\u0026ndash;241, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.psychres.2008.05.007\u003c/span\u003e\u003cspan address=\"10.1016/j.psychres.2008.05.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLeckman, J. F. \u003cem\u003eet al.\u003c/em\u003e The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28, 566\u0026ndash;573, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/00004583-198907000-00015\u003c/span\u003e\u003cspan address=\"10.1097/00004583-198907000-00015\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1989).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKutuk, M. O. \u003cem\u003eet al.\u003c/em\u003e Cytokine expression profiles in Autism spectrum disorder: A multi-center study from Turkey. Cytokine 133, 155152, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cyto.2020.155152\u003c/span\u003e\u003cspan address=\"10.1016/j.cyto.2020.155152\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGorman, D. A. \u0026amp; Abi-Jaoude, E. Uncovering the complexity of Tourette syndrome, little by little. Br J Psychiatry 204, 6\u0026ndash;8, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1192/bjp.bp.113.135996\u003c/span\u003e\u003cspan address=\"10.1192/bjp.bp.113.135996\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePaschou, P., Fernandez, T. V., Sharp, F., Heiman, G. A. \u0026amp; Hoekstra, P. J. Genetic susceptibility and neurotransmitters in Tourette syndrome. Int Rev Neurobiol 112, 155\u0026ndash;177, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/B978-0-12-411546-0.00006-8\u003c/span\u003e\u003cspan address=\"10.1016/B978-0-12-411546-0.00006-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKanaan, A. S. \u003cem\u003eet al.\u003c/em\u003e Convergent imaging-transcriptomic evidence for disturbed iron homeostasis in Gilles de la Tourette syndrome. Neurobiol Dis 185, 106252, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.nbd.2023.106252\u003c/span\u003e\u003cspan address=\"10.1016/j.nbd.2023.106252\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTsetsos, F. \u003cem\u003eet al.\u003c/em\u003e Genome-wide Association Study Points to Novel Locus for Gilles de la Tourette Syndrome. Biol Psychiatry, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.biopsych.2023.01.023\u003c/span\u003e\u003cspan address=\"10.1016/j.biopsych.2023.01.023\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLamothe, H., Tamouza, R., Hartmann, A. \u0026amp; Mallet, L. Immunity and Gilles de la Tourette syndrome: A systematic review and meta-analysis of evidence for immune implications in Tourette syndrome. Eur J Neurol 28, 3187\u0026ndash;3200, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ene.14983\u003c/span\u003e\u003cspan address=\"10.1111/ene.14983\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFarhat, L. C. \u003cem\u003eet al.\u003c/em\u003e Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. Lancet Child Adolesc Health 7, 112\u0026ndash;126, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S2352-4642(22)00316-9\u003c/span\u003e\u003cspan address=\"10.1016/S2352-4642(22)00316-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSteinman, L. Inflammatory cytokines at the summits of pathological signal cascades in brain diseases. Sci Signal 6, pe3, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/scisignal.2003898\u003c/span\u003e\u003cspan address=\"10.1126/scisignal.2003898\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKummer, K. K., Zeidler, M., Kalpachidou, T. \u0026amp; Kress, M. Role of IL-6 in the regulation of neuronal development, survival and function. Cytokine 144, 155582, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cyto.2021.155582\u003c/span\u003e\u003cspan address=\"10.1016/j.cyto.2021.155582\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarcinowicz, P. \u003cem\u003eet al.\u003c/em\u003e A Meta-Analysis of the Influence of Antipsychotics on Cytokines Levels in First Episode Psychosis. J Clin Med 10, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/jcm10112488\u003c/span\u003e\u003cspan address=\"10.3390/jcm10112488\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTao, Y. \u003cem\u003eet al.\u003c/em\u003e Changes of Cytokines in Children With Tic Disorder. Front Neurol 12, 800189, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fneur.2021.800189\u003c/span\u003e\u003cspan address=\"10.3389/fneur.2021.800189\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLeckman, J. F. \u003cem\u003eet al.\u003c/em\u003e Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. Biol Psychiatry 57, 667\u0026ndash;673, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.biopsych.2004.12.004\u003c/span\u003e\u003cspan address=\"10.1016/j.biopsych.2004.12.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYeon, S. M. \u003cem\u003eet al.\u003c/em\u003e A cytokine study of pediatric Tourette's disorder without obsessive compulsive disorder. Psychiatry Res 247, 90\u0026ndash;96, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.psychres.2016.11.005\u003c/span\u003e\u003cspan address=\"10.1016/j.psychres.2016.11.005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMatz, J. \u003cem\u003eet al.\u003c/em\u003e Altered monocyte activation markers in Tourette's syndrome: a case-control study. BMC Psychiatry 12, 29, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/1471-244X-12-29\u003c/span\u003e\u003cspan address=\"10.1186/1471-244X-12-29\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJones, H. F. \u003cem\u003eet al.\u003c/em\u003e Maternal autoimmunity and inflammation are associated with childhood tics and obsessive-compulsive disorder: Transcriptomic data show common enriched innate immune pathways. Brain Behav Immun 94, 308\u0026ndash;317, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bbi.2020.12.035\u003c/span\u003e\u003cspan address=\"10.1016/j.bbi.2020.12.035\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcCoy, M. K. \u0026amp; Tansey, M. G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5, 45, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/1742-2094-5-45\u003c/span\u003e\u003cspan address=\"10.1186/1742-2094-5-45\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Heesch, F. \u003cem\u003eet al.\u003c/em\u003e Systemic tumor necrosis factor-alpha decreases brain stimulation reward and increases metabolites of serotonin and dopamine in the nucleus accumbens of mice. Behav Brain Res 253, 191\u0026ndash;195, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bbr.2013.07.038\u003c/span\u003e\u003cspan address=\"10.1016/j.bbr.2013.07.038\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRochfort, K. D. \u0026amp; Cummins, P. M. The blood-brain barrier endothelium: a target for pro-inflammatory cytokines. Biochem Soc Trans 43, 702\u0026ndash;706, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1042/BST20140319\u003c/span\u003e\u003cspan address=\"10.1042/BST20140319\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBanks, W. A. \u0026amp; Erickson, M. A. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 37, 26\u0026ndash;32, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.nbd.2009.07.031\u003c/span\u003e\u003cspan address=\"10.1016/j.nbd.2009.07.031\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMartino, D., Dale, R. C., Gilbert, D. L., Giovannoni, G. \u0026amp; Leckman, J. F. Immunopathogenic mechanisms in tourette syndrome: A critical review. Mov Disord 24, 1267\u0026ndash;1279, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/mds.22504\u003c/span\u003e\u003cspan address=\"10.1002/mds.22504\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGhorbani, M. M. \u003cem\u003eet al.\u003c/em\u003e Evaluation of IL-17 Serum Level, Brain Inflammation and Demyelination in Experimental Autoimmune Encephalomyelitis C57BL/6 Mice Model with Different Doses of Myelin Oligodendrocyte Glycoprotein. Iran J Allergy Asthma Immunol 18, 300\u0026ndash;309, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.18502/ijaai.v18i3.1123\u003c/span\u003e\u003cspan address=\"10.18502/ijaai.v18i3.1123\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGreen, H. F., Khosousi, S. \u0026amp; Svenningsson, P. Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson's Disease. J Parkinsons Dis 9, 705\u0026ndash;709, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3233/JPD-191699\u003c/span\u003e\u003cspan address=\"10.3233/JPD-191699\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen, J., Liu, X. \u0026amp; Zhong, Y. Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases. Front Aging Neurosci 12, 566922, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fnagi.2020.566922\u003c/span\u003e\u003cspan address=\"10.3389/fnagi.2020.566922\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMelnikov, M., Belousova, O., Murugin, V., Pashenkov capital Em, C. \u0026amp; Boysmall ka, C. o. C. A. The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J Neuroimmunol 292, 97\u0026ndash;101, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jneuroim.2016.01.020\u003c/span\u003e\u003cspan address=\"10.1016/j.jneuroim.2016.01.020\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNakano, K. \u003cem\u003eet al.\u003c/em\u003e Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 373, 286\u0026ndash;291, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bbrc.2008.06.012\u003c/span\u003e\u003cspan address=\"10.1016/j.bbrc.2008.06.012\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBok, E., Cho, E. J., Chung, E. S., Shin, W. H. \u0026amp; Jin, B. K. Interleukin-4 Contributes to Degeneration of Dopamine Neurons in the Lipopolysaccharide-treated Substantia Nigra in vivo. Exp Neurobiol 27, 309\u0026ndash;319, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.5607/en.2018.27.4.309\u003c/span\u003e\u003cspan address=\"10.5607/en.2018.27.4.309\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHanuscheck, N. \u003cem\u003eet al.\u003c/em\u003e Interleukin-4 receptor signaling modulates neuronal network activity. J Exp Med 219, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1084/jem.20211887\u003c/span\u003e\u003cspan address=\"10.1084/jem.20211887\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePatel, M. R. \u0026amp; Weaver, A. M. Astrocyte-derived small extracellular vesicles promote synapse formation via fibulin-2-mediated TGF-beta signaling. Cell Rep 34, 108829, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.celrep.2021.108829\u003c/span\u003e\u003cspan address=\"10.1016/j.celrep.2021.108829\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrionne, T. C., Tesseur, I., Masliah, E. \u0026amp; Wyss-Coray, T. Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40, 1133\u0026ndash;1145, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0896-6273(03)00766-9\u003c/span\u003e\u003cspan address=\"10.1016/s0896-6273(03)00766-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2003).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDepino, A. M., Lucchina, L. \u0026amp; Pitossi, F. Early and adult hippocampal TGF-beta1 overexpression have opposite effects on behavior. Brain Behav Immun 25, 1582\u0026ndash;1591, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bbi.2011.05.007\u003c/span\u003e\u003cspan address=\"10.1016/j.bbi.2011.05.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eElamin, I., Edwards, M. J. \u0026amp; Martino, D. Immune dysfunction in Tourette syndrome. Behav Neurol 27, 23\u0026ndash;32, doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3233/BEN-120295\u003c/span\u003e\u003cspan address=\"10.3233/BEN-120295\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Tic disorders, Cytokines, Immune system, Inflammation, Tourette syndrome","lastPublishedDoi":"10.21203/rs.3.rs-3813261/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3813261/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe etiology of tic disorders (TDs) is not precisely known, although several lines of evidence suggest involvement of the immune system in pathogenesis. Here, we aimed to determine the expression levels of pro-inflammatory and anti-inflammatory cytokines in children with TD and compare them with those of healthy controls. Furthermore, we also evaluated their association with clinical variables in the TD group. Within the study period, 88 children with tic disorders and 111 healthy control children were enrolled. Most children with tic disorders were diagnosed with Tourette\u0026rsquo;s disorder (n\u0026thinsp;=\u0026thinsp;47, 53.4%) or persistent motor tic disorder (n\u0026thinsp;=\u0026thinsp;39, 44.3%), while the remainder (n\u0026thinsp;=\u0026thinsp;2, 2.3%) were diagnosed with persistent vocal tic disorder. We found that children with tic disorders had significantly elevated levels of IL-1β, TNF-α, IL-6 and IL-4 expression, while healthy control cases presented with increased levels of IL-17. Our findings provide a molecular landscape of cytokine expression in children with TD, which may suggest a proinflammatory state not affected by the presence of comorbidity and symptom severity. Delineating the contribution of alterations in the immune system to the pathogenesis of tic disorders will have critical implications for diagnosis and therapeutic interventions.\u003c/p\u003e","manuscriptTitle":"Cytokine Expression Profiles in Children and Adolescents with Tic Disorders.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-01-01 18:58:30","doi":"10.21203/rs.3.rs-3813261/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-01-16T02:46:11+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-01-02T18:57:35+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"942cf81f-0593-4fd4-b3c6-efc909ba1f5f","date":"2023-12-31T07:50:09+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"07e521c3-dc7f-4617-876b-d4eb5664ea69","date":"2023-12-30T12:56:33+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2023-12-29T21:45:49+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2023-12-29T21:41:15+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2023-12-29T11:28:13+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2023-12-29T11:26:01+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2023-12-27T17:43:13+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2fb65821-7aee-4edb-a2f5-474007baf565","owner":[],"postedDate":"January 1st, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":27880841,"name":"Health sciences/Diseases"},{"id":27880842,"name":"Health sciences/Diseases/Psychiatric disorders"},{"id":27880843,"name":"Health sciences/Health care/Quality of life"},{"id":27880844,"name":"Health sciences/Risk factors"}],"tags":[],"updatedAt":"2024-05-14T04:53:54+00:00","versionOfRecord":[],"versionCreatedAt":"2024-01-01 18:58:30","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3813261","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3813261","identity":"rs-3813261","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}